The present invention describes cytotoxic compounds with an intracellular target that can selectively enter tumor cells through specific receptors on the cell surface. More
Exclusive license for use of gabapentin in the above indications in EU, Canada, Australia, New Zealand. US Phase 3 trials of MR-gabapentin for menopause by PharmaNova’s US licensee (Depomed, Inc) will complete in 3Q 2009; Co-promotion in US is possible. More
Antibodies generated in mouse lymphoma cells used to recognize human breast cancer. The antibodies in their current and modified forms can be used in the diagnosis, prognosis, and subsequent treatment of certain human breast cancers. Diagnosis of... More
US based researchers are seeking licensing partners for the further development of their antigen which is intended for the treatment of breast cancer but could also have applications in ovarian cancer and other malignancies. More
These cell lines (based on the widely used B16 murine melanoma cell line) were transduced with retroviral vectors encoding cDNA for either CXCR4 or CCR10 under control of a TET-dependent promoter. More
The technology describes the humanization of a murine anti-carcinoma antibody CC49 which has been shown to react with Tumor Associated Glycoprotein 72 (TAG-72), an antigen which is expressed on human breast, ovarian, colorectal, and other carcinomas. More
A highly metastatic murine breast cancer cell line that provides an excellent mouse model for fundamental as well as therapeutic studies of human breast cancer metastasis. More
The present invention concerns a stable lipid assembly comprising a biologically active lipid having a hydrophobic region and a polar headgroup. These specific lipid assemblies comprise the biologically active lipid, ceramide, a lipid derivatized... More
A method of antitumor therapy is described in which administration of a chemotherapeutic drug, encapsulated in liposomes, is supplemented by administration of an immunostimulating cytokine. The cytokine is preferably also encapsulated in liposomes.... More
All rights reserved. Terms and Conditions | Contact us
